Kings Research today announced the release of its latest market intelligence study, “Global Amlodipine Besylate Market: Size, Share, Trends & Forecast 2024–2031.” The report provides a detailed assessment of market trends, clinical drivers, regional dynamics, and competitive developments.
According to Kings Research, the global amlodipine besylate market was valued at USD 1,933.0 million in 2024, and is projected to reach USD 2,539.5 million by 2031, expanding at a CAGR of 3.98% during the forecast period. This growth reflects the rising global burden of hypertension and cardiovascular disease, increasing adoption of combination therapies, and continued innovation in pharmaceutical formulations that improve patient adherence.
Amlodipine besylate is a calcium channel blocker used to treat high blood pressure and chronic chest pain (angina). By relaxing blood vessels and reducing the heart’s workload, the medication lowers the risk of heart attacks, strokes, and kidney complications. Its widespread use as both a standalone therapy and in fixed-dose combinations makes it a cornerstone of modern hypertension management.
Kings Research identifies the following factors propelling market expansion
- Escalating Hypertension Prevalence Worldwide
The World Health Organization (WHO) estimates that 1.28 billion adults aged 30–79 globally have hypertension, and 46% are unaware of their condition. (Source: pmc.ncbi.nlm.nih.gov) In the United States alone, the Centers for Disease Control and Prevention (CDC) reports that nearly half of all adults (about 119 million people) have hypertension, while only 25% achieve adequate control of their blood pressure. Rapid urbanization, sedentary lifestyles, and high salt intake continue to elevate risk levels across both developed and emerging economies.
- Combination Therapy Adoption
Physicians increasingly prescribe amlodipine with ACE inhibitors, ARBs, or diuretics to achieve faster, more consistent blood pressure control. A study in the Journal of the American College of Cardiology found that combination therapy is significantly more effective in reducing blood pressure than single-drug regimens.
- Pharmaceutical Innovation & Generics
Expanded production of cost-effective generic formulations is increasing accessibility, particularly in price-sensitive markets. Advanced delivery systems such as extended-release tablets improve patient compliance by reducing dosing frequency.
- Demographic Shifts
Aging populations across Asia-Pacific, Europe, and North America are adding millions of new patients to the treatment pool every year, amplifying long-term demand.
For healthcare providers and payers, amlodipine besylate offers
- Clinical Reliability: Decades of efficacy data support its use as a first-line antihypertensive.
- Cost Efficiency: Widespread generic availability reduces treatment costs for health systems and patients.
- Therapeutic Flexibility: Works well as a monotherapy and in combination treatments, supporting personalized care plans.
Regional Outlook
- North America: Accounted for 34.56% of global revenue (USD 645.2 million) in 2023, supported by high hypertension prevalence, robust insurance coverage, and strong R&D activity.
- Asia-Pacific: Projected to grow at a 5.09% CAGR through 2031, driven by large aging populations, rising healthcare awareness, and government-led preventive health campaigns.
- Europe, Latin America, Middle East & Africa: Demonstrating steady growth due to public health initiatives promoting early detection and management of cardiovascular disease.
Competitive Landscape
The market remains competitive with both multinational and regional pharmaceutical firms expanding through R&D, partnerships, and cost-efficient manufacturing. Key companies include Apotex Inc., Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Pharmaceuticals, Inc., Mylan Pharmaceuticals ULC, Oxford Pharm, and Pfizer Inc.
The full Kings Research report offers detailed segmentation by form, sales channel, and region, along with competitive benchmarking and in-depth market forecasts. To request a sample or access the complete report, please visit https://www.kingsresearch.com/amlodipine-besylate-market-853.
About Kings Research
Kings Research is a global provider of syndicated research reports and consulting services, helping organizations navigate emerging markets, assess opportunities, and make informed business decisions.
All market data are sourced from Kings Research proprietary analysis, validated against credible public sources such as the World Health Organization (www.who.int) and the U.S. Centers for Disease Control and Prevention (www.cdc.gov).